(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Meiragtx Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MGTX's revenue for 2024 to be $4,326,952,645, with the lowest MGTX revenue forecast at $4,326,952,645, and the highest MGTX revenue forecast at $4,326,952,645. On average, 1 Wall Street analysts forecast MGTX's revenue for 2025 to be $17,314,232,297, with the lowest MGTX revenue forecast at $17,314,232,297, and the highest MGTX revenue forecast at $17,314,232,297.
In 2026, MGTX is forecast to generate $21,451,102,131 in revenue, with the lowest revenue forecast at $21,451,102,131 and the highest revenue forecast at $21,451,102,131.